Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Brand profile · Biotechnology Research
Zelira Therapeutics is a Biotechnology Research brand in Perth, Western Australia. Publicly held, at zeliratx.com. It holds one address on record, all in Australia. It employs 10 people, on the record. It lists medicinal cannabis and clinical trials among its specialties. One Australian registration (ABN) is a confirmed match. Its latest round on record is Post IPO equity, US$8.6M. It is listed alongside five similar brands, mostly in Pharmaceutical Manufacturing.
ABN27103782378
| ZELIRA THERAPEUTICS LIMITED | ABN 27103782378 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Zelira Therapeutics Ltd (formerly Zelda Therapeutics) is a leading global therapeutic medicinal cannabis company with access to the world’s largest and fastest growing cannabis markets.
www.zeliratx.com
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
| Rounds | 2 |
|---|---|
| Axis | 2015 to 2026 |
| Post IPO equity · 15 Mar 2023 | US$ 8.6M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Hiring, headcount and registry-change signals, streamed to members.
Registry-filed capital and financial indicators, standardised by TheGrid.
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
One Western Australia entity on the ABR: ZELIRA THERAPEUTICS LIMITED (ABN 27 103 782 378), high confidence.
10 counted staff profiles at January 2026, inside the self-reported 2–10 band.
One address on record, Australia only. Primary: St Georges Ter, Perth, Western Australia 6000.
Two rounds. Latest 15 March 2023: post IPO equity, US$8,600,000.
Six tags on the brand's own list, among them medicinal cannabis and clinical trials.
4 profiles list Zelira Therapeutics as a peer — 56th percentile in Biotechnology Research. It lists ten peers of its own. Biotome Pty Ltd and NeuroScientific Biopharmaceuticals Ltd list it back.